Extended 39-Week Study of PSMA ADC Following the Initial 12-Week Dose-escalation Study in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer [EXTENSION OF 700037137].
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2013
At a glance
- Drugs PSMA ADC (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 01 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Feb 2013 New trial record